August proved volatile for PMS funds, with several small and midcap strategies logging steep losses—Valcreate’s Lifesciences fund plunged 10.19%. Yet, a few portfolios like Wallfort’s Avenue Fund and Valcreate’s Digital Disruption strategy posted modest gains, highlighting sharp performance divergence.
Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth
Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO